ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis’ Tafinlar plus Mekinist shows long-term benefit in advanced melanoma
September 18, 2020A combination of Novartis’ cancer meds Tafinlar (dabrafenib) and Mekinist (trametinib) has demonstrated long-term benefit in advanced melanoma patients after five years of treatment. -
Novartis' melanoma combo fails in PhIII
August 24, 2020Novartis has announced that its investigational immunotherapy spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) failed to improve progression-free survival in patients with advanced melanoma. -
FiercePharmaAsia—Sun’s quarterly loss, BeiGene’s $175M public offering, Biocon plant’s extensive pro
August 14, 2017Sun Pharma took a hit with a 9.51 billion rupees antitrust settlement over Modafinil, a sleep disorder treatment.
Pharma Sources Insight January 2025
